Comment from Cordis

Summary: The commenter, representing a business entity in the pharmaceutical industry, supports the SUPAC guidances but suggests several improvements to enhance clarity and reduce regulatory burden. They recommend incorporating more detailed risk-based principles from ICH Q9(R1), adding specific sections for combination products and various change types (like supplier or cleanroom changes), and potentially consolidating duplicative documents into a single guidance with specific appendices.